Cardiac Dimensions, Inc.

Cardiac Dimensions, Inc. is a medical device company focused on transcatheter treatment of functional mitral regurgitation (FMR) and heart failure. The company develops and commercializes the Carillon Mitral Contour System, a percutaneous, minimally invasive device designed to treat FMR by working with the heart's natural structure and function via coronary sinus-based mitral annuloplasty. The Carillon system is delivered through a catheter-based procedure typically lasting about one hour, without preventing access to other cardiac therapies. The device is CE-marked (0344) and commercially available in Europe and other jurisdictions. In the United States, the Carillon system is currently investigational, limited to clinical trials including the EMPOWER trial, which is enrolling heart failure patients with large ventricles and FMR. Multiple published European clinical studies demonstrate improvements in patient quality of life, mitral regurgitation severity, and left ventricular volume. The company serves interventional cardiologists, heart failure specialists, and hospital cardiology programs. As of 2025, Cardiac Dimensions has completed Series E financing ($53 million raised in March 2025) and appointed William T. Abraham, MD as Chief Medical Officer. The organization maintains headquarters in Kirkland, Washington, with operations in Europe (Offenbach, Germany) and Australia (Sydney). Clinical evidence includes multiple peer-reviewed publications in European Heart Journal, JACC: Cardiovascular Interventions, and other cardiology journals documenting long-term outcomes and mechanistic benefits of the Carillon therapy.